Marriage of synthetic biology and 3D printing produces programmable living materials
Applications could someday include biomanufacturing and sustainable construction
Scientists are harnessing cells to make new types of materials that can grow, repair themselves and even respond to their environment. These solid “engineered living materials” are made by embedding cells in an inanimate matrix that’s formed in a desired shape. Now, researchers report in ACS Central Science that they have 3D printed a bioink containing plant cells that were then genetically modified, producing programmable materials. Applications could someday include biomanufacturing and sustainable construction.
Between day one (left) and day 14 (right), plant cells 3D printed in hydrogel grow and begin flourishing into yellow clusters.
Adapted from ACS Central Science 2024, DOI: 10.1021/acscentsci.4c00338
Recently, researchers have been developing engineered living materials, primarily relying on bacterial and fungal cells as the live component. But the unique features of plant cells have stirred enthusiasm for their use in engineered plant living materials (EPLMs). However, the plant cell-based materials created to date have had fairly simple structures and limited functionality. Ziyi Yu, Zhengao Di and colleagues wanted to change that by making intricately shaped EPLMs containing genetically engineered plant cells with customizable behaviors and capabilities.
The researchers mixed tobacco plant cells with gelatin and hydrogel microparticles that contained Agrobacterium tumefaciens, a bacterium commonly used to transfer DNA segments into plant genomes. This bioink mixture was then 3D printed on a flat plate or inside a container filled with another gel to form shapes such as grids, snowflakes, leaves and spirals. Next, the hydrogel in the printed materials was cured with blue light, hardening the structures. During the ensuing 48 hours, the bacteria in the EPLMs transferred DNA to the growing tobacco cells. The materials were then washed with antibiotics to kill the bacteria. In the following weeks, as the plant cells grew and replicated in the EPLMs, they began producing proteins dictated by the transferred DNA.
In this proof-of-concept study, the transferred DNA enabled the tobacco plant cells to produce green fluorescent proteins or betalains — red or yellow plant pigments that are valued as natural colorants and dietary supplements. By printing a leaf-shaped EPLM with two different bioinks — one that created red pigment along the veins and the other a yellow pigment in the rest of the leaf — the researchers showed that their technique could produce complex, spatially controlled and multifunctional structures. Such EPLMs, which combine the traits of living organisms with the stability and durability of non-living substances, could find use as cellular factories to churn out plant metabolites or pharmaceutical proteins, or even in sustainable construction applications, according to the researchers.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Leumann & Uhlmann AG - Muttenz, Switzerland
Innogenetics extends its diagnostics product portfolio for Alzheimer's disease with new products
Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Roche to leave S1P1 alliance following comprehensive portfolio review and prioritization
Lexicon Genetics Granted Exclusive License to Cellectis' Homologous Recombination Technology
Astellas to Acquire AMEVIVE® (alefacept) - Acquisition of psoriasis product deepens Astellas' Commitment to Dermatology franchise
Apogenix GmbH - Heidelberg, Germany
Medgenics consolidates corporate and R&D operations into new office facility
LECO Corporation - St. Joseph, USA
Eckert & Ziegler subsidiary IBt Bebig acquires specialist for medical planning software
Merck Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
